Wellesley Pharmaceuticals Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$10M
- Investors
-
4
Wellesley Pharmaceuticals General Information
Description
Developer of a pharmaceutical platform intended to treat nocturia disease of patients. The company's platform assists in treating the frequent need to urinate at night and eliminating nocturia symptoms which can be disseminated, enabling patients to sleep well at night without using the bathroom.
Contact Information
Website
www.wellesleypharma.comCorporate Office
- 3 Valley View Drive
- Newtown, PA 18940
- United States
Corporate Office
- 3 Valley View Drive
- Newtown, PA 18940
- United States
Wellesley Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 18-Apr-2016 | $10M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series C) | 01-Apr-2015 | Completed | Clinical Trials - Phase 2 | |||
| 2. Angel (individual) | 01-Oct-2014 | $550K | $1.05M | Completed | Clinical Trials - Phase 2 | |
| 1. Angel (individual) | 11-Jun-2014 | $500K | $500K | Completed | Clinical Trials - Phase 2 |
Wellesley Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Wellesley Pharmaceuticals Patents
Wellesley Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2019069991-A | Pharmaceutical formulations for reducing bladder spasms and use methods thereof | Pending | 27-Dec-2018 | ||
| JP-2019031556-A | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | Pending | 31-Oct-2018 | ||
| US-20190374474-A1 | Pharmaceutical compositions and methods for weight loss | Inactive | 11-Jun-2018 | ||
| AU-2016370313-A1 | Composition for reducing frequency of urination, method of making and use thereof | Inactive | 18-Dec-2015 | ||
| CA-3008628-A1 | Composition for reducing frequency of urination, method of making and use thereof | Inactive | 18-Dec-2015 | A61K9/28 |
Wellesley Pharmaceuticals Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Axella Bioventures | Venture Capital | Minority | ||
| Keiretsu Forum | Angel Group | Minority |
Wellesley Pharmaceuticals FAQs
-
When was Wellesley Pharmaceuticals founded?
Wellesley Pharmaceuticals was founded in 2011.
-
Where is Wellesley Pharmaceuticals headquartered?
Wellesley Pharmaceuticals is headquartered in Newtown, PA.
-
What industry is Wellesley Pharmaceuticals in?
Wellesley Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Wellesley Pharmaceuticals a private or public company?
Wellesley Pharmaceuticals is a Private company.
-
What is the current valuation of Wellesley Pharmaceuticals?
The current valuation of Wellesley Pharmaceuticals is .
-
What is Wellesley Pharmaceuticals’s current revenue?
The current revenue for Wellesley Pharmaceuticals is .
-
How much funding has Wellesley Pharmaceuticals raised over time?
Wellesley Pharmaceuticals has raised $12.6M.
-
Who are Wellesley Pharmaceuticals’s investors?
, , Axella Bioventures, and Keiretsu Forum have invested in Wellesley Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
